Initial Phase 2 Trial of a Nicotinic Agonist in Schizophrenia

Abstract
Objective: Nicotinic acetylcholine receptors are possible therapeutic targets for schizophrenia, as shown by neurobiological and molecular evidence for deficiencies in expression of α 7 -nicotinic ...

This publication has 37 references indexed in Scilit: